During the past decade, General Hospital of Athens G. Gennimatas conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 17 clinical trials were completed, i.e. on average, 51.5% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 12 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "General Hospital of Athens G. Gennimatas" #1 sponsor was "Bayer" with 6 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Elpen Pharmaceutical Co. Inc." with 4 trials sponsored and "Janssen Research & Development, LLC" with 4 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "General Hospital of Athens G. Gennimatas" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Amalia Fleming Prefecture General Hospital of Melissia" with 1 trials as a collaborator and "Attikon Hospital" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "General Hospital of Athens G. Gennimatas" are "Heart Failure" (6 trials), "Acromegaly" (2 trials), "Diabetes Mellitus, Type 2" (2 trials), "Hypertension" (2 trials) and "Systemic Lupus Erythematosus" (2 trials). Many other conditions were trialed in "General Hospital of Athens G. Gennimatas" in a lesser frequency.

Most popular intervention types in "General Hospital of Athens G. Gennimatas" are "Drug" (30 trials), "Other" (6 trials), "Device" (3 trials), "Biological" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Baricitinib" (2 trials), "Empagliflozin" (2 trials), "Golimumab" (2 trials) and "Guselkumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "General Hospital of Athens G. Gennimatas" are 43 trials for "All" genders.

Currently, there are NaN active trials in "General Hospital of Athens G. Gennimatas". 1 are not yet recruiting, 7 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in General Hospital of Athens G. Gennimatas, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in General Hospital of Athens G. Gennimatas, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".